WO2006134409A2 - Synergistic prebiotic compositions - Google Patents

Synergistic prebiotic compositions Download PDF

Info

Publication number
WO2006134409A2
WO2006134409A2 PCT/HU2006/000051 HU2006000051W WO2006134409A2 WO 2006134409 A2 WO2006134409 A2 WO 2006134409A2 HU 2006000051 W HU2006000051 W HU 2006000051W WO 2006134409 A2 WO2006134409 A2 WO 2006134409A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
ginseng
components
partial hydrolysates
oligosaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2006/000051
Other languages
French (fr)
Other versions
WO2006134409A3 (en
Inventor
Csaba József JÁSZBERÉNYI
Tamás János SZAKÁCS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to SI200632398T priority Critical patent/SI1893221T1/en
Priority to EP06744405.9A priority patent/EP1893221B8/en
Priority to CA2611935A priority patent/CA2611935C/en
Priority to EA200800034A priority patent/EA017289B1/en
Priority to US11/917,236 priority patent/US20080261916A1/en
Publication of WO2006134409A2 publication Critical patent/WO2006134409A2/en
Publication of WO2006134409A3 publication Critical patent/WO2006134409A3/en
Anticipated expiration legal-status Critical
Priority to US13/353,639 priority patent/US20120121621A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D10/00—Batters, dough or mixtures before baking
    • A21D10/002—Dough mixes; Baking or bread improvers; Premixes
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/16—Fatty acid esters
    • A21D2/165—Triglycerides
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/181—Sugars or sugar alcohols
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/245—Amino acids, nucleic acids
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/30—Organic phosphorus compounds
    • A21D2/32—Phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
    • A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
    • A23L13/426—Addition of proteins, carbohydrates or fibrous material from vegetable origin other than sugars or sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to synergistic prebiotic compositions in which fructose polymers of GF n or F m structures, either containing a glucose (G) end-group and one or more prebiotic components from a group of prebiotics consisting of modified or unmodified starch and suitable partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fructo-oligosacharides (FOS), lactulose, galactomannan and suitable hydrolysates thereof, indigestible polydextrose, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), acemannan, lentinan or beta-glucan and partial hydrolysates thereof, polysaccharides P and K (PSP, PSK), tagatose and if desired phytosterols and lecithins are used, optionally with other plant extracts or dried plant powder
  • Prebiotics are in most cases oligo- and/or polysaccharides that are not digested in the stomach and small intestine and reach the colon more or less intact (Roberfroid MB. Prebiotics: preferential substrates for specific germs? American Journal of Clinical Nutrition, 2001 :73(2) 406S-409S). However, colonic bacteria are able to use these compounds (Macfarlane GT, Gibson GR. Metabolic activities of the normal colonic flora. In: Gibson SAW, ed. Human health - the contribution of microorganisms. London: Springer- Verlag, 1994:17-52).
  • the advantageous prebiotic components are capable to increase the amount of probiotic microorganisms in the colonic microflora (Collins MD, Gibson GR.
  • compositions exert a complex physiological influence in the host (Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004:20(2): 146-155). These include the positive change in lipid and cholesterol levels, limiting the occurrence and amount of dangerous or disadvantegous resident bacteria (these include the dangerous Helicobacter pylori or Clostridia) or invading colonic bacteria (Aim L.
  • the colonization starts during and after birth and the formation of the complex colonic microflora proceeds for years.
  • the colonic microflora is a changeable biodynamic ecosystem.
  • the colon of a child is colonized with a hundred or a couple of hundreds strains of bacteria. This develops further and the colonic microflora then remains a close-knit commensal bacterial ecosystem until the age of about 60 years. After that this systems gets somewhat loose, allowing new (unwanted) members to get attached to the system. This contributes or may contribute to the decline of health of the elderly people.
  • the microbes in the colon are capable to exert the following positive effects:
  • compositions can also be utilized in fodder and feed additives (Abe F, Ishibashi N, Shimamura S. Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets. J. Dairy Sci. 1995:78:2838-2846.).
  • said compositions are capable to reduce symptoms of allergy (Noverr MC, Hufmagle GB. Does the microbiota regulate immune responses outside the gut? Trends in Microbiology 2004:12:562-568). Said compositions are able to positively modulate the immune system (Gut Flora, Nutrition and Immunity, Fuller R., Perdig ⁇ n G., Eds., Blackwell Publishing, 2003).
  • phytosterols as well as their hydrogenated counterparts, phytostanols and their esters are capable to reduce the total cholesterol and low density lipoprotein cholesterol (LDL) levels in the human blood.
  • LDL low density lipoprotein cholesterol
  • Consumption of plant sterols is not a new phenomenon. In fact, it precedes that of the human development.
  • Our close relative primates continue to consume a much higher amount of phytosterols daily than the modern man.
  • the typically 100 to 300 mg/day plant sterol consumption of humans today is much less than the amount required to achieve a meaningful change in blood lipid parameters.
  • the effect is complex. It is achieved by the phytosterol inhibition of the absorption of the exogenous (food) cholesterol and also by the inhibition of the reabsorption of the cholesterol transported by the endogenous enterohepatic circulation. These result in increased cholesterol clearance.
  • the cholesterol and phytosterol transport can be modulated by the application of plant sterols in lecithin micelles (Ostlund RE, Jr., Spilburg CA, Stenson WF. Sitostanol administered in lecithin micelles potentially reduces cholesterol absorption in humans. American Journal of Clinical Nutrition, 1999:70:826-831).
  • Phytosterols are also capable to prevent the development of benign prostatic hyperplasia (BPH) (Wilt TJ, MacDonald R, Ishani A.
  • Beta-sitosterol for the treatment of benign prostatic hyperplasia a systematic review. BJU Int. 1999;83:976-983).
  • the successful and efficient application of phytosterol esters in bakery products for the reduction of plasma LDL-cholesterol has also been documented (Quilez J, Rafecas M, Brufau G, Garcia-Lorda P, Megias I, Bull ⁇ M, Ruiz JA, Salas-Salvado J, J. Nutr. 2003:133:3103-3109 and references there cited).
  • compositions comprising the combination according to the present invention may be used as medicaments, cosmetics, food and fodder additives, dietary supplements, as well as prebiotic and symbiotic food and fodder.
  • the present invention relates to synergistic prebiotic compositions comprising prebiotic components selected from fructose polymers GF n and F mj either containing a glucose (G) end-group, or without this glucose end-group and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fructo- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.
  • compositions according to the present invention comprise prebiotic components selected from fructose polymers GF n and F m, either containing a glucose (G) end-group, or without this glucose end-group and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed .
  • prebiotic components selected from fructose polymers GF n and F m, either containing a glucose (G) end-group, or without this glucose end-group and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed .
  • inulin natural oligofructoses, fructo- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo- oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.
  • FOS fructo- oligosaccharides
  • lactulose galactomannan and suitable partial hydrolysates thereof
  • indigestible polydextrose acemannan
  • various gums indigestible dextrin and partial hydrolysates thereof
  • trans-galacto-oligosaccharides GOS
  • XOS xyl
  • the fructose polymers OfGF n or F m structures are linear fructose polymers having either a glucose (G) and-group, or being without this glucose and-group.
  • Oligofructoses are consisted of 3 to 10 carbohydrate units.
  • chicory inulin contains 10 to 60 carbohydrate units, typically with 27 carbohydrates (fructoses with our without one glucose end-group and a fructose chain).
  • Other plants may produce different fructans. These fructans are capable to increase the number of colonized and planktonic bacteria in the larges intestine.
  • the local chemical carcinogenesis can also be the result of the formation of secondary bile acids.
  • These secondary bile acids are often formed upon the action of enzymes produced by resident Clostridia.
  • the chance of secondary bile acid formation can also be reduced. This can be demonstrated by measuring the faecal primary/secondary bile acid ratio.
  • prebiotics can be selected from a group of prebiotics consisting of various gums (guar gum, xanthan gum, locust been gum), carob seed flour, oat bran, rice bran, barley, modified or unmodified starch and suitable partial hydrolysates thereof, partially hydrolysed inulin, natural or synthetic/biosynthetic oligofructoses, fructo- oligosacharides (FOS), lactulose, galactomannan and suitable hydrolysates thereof, indigestible polydextrose, indigestible dextrin and partial hydrolysates thereof, trans- galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), acemannan, lentinan or beta-glucan and partial hydrolysates thereof, polysaccharides P and K (PSP, PSK), tagatose, various fungal oligosaccharides and polysaccharides, together with other components.
  • gums
  • Further embodiment of the invention is the application of various phytosterols in these compositions.
  • These phytosterols can be found in various plants.
  • the mixture of phytosterols used in foods are of soy or tall oil origin.
  • Corn fiber oil is also very rich in phytosterols and their derivatives.
  • LDL low density lipoprotein
  • TC total cholesterol
  • sterols and stanols on the one hand and their esterified counterparts on the other are all suitable for this purpose. The question remains whether these compounds are soluble in the media of applications.
  • a further embodiment of this invention is the formation of supramolecular compositions.
  • SMSA spontaneous multicomponent supramolecular self- assembly
  • lecithins and/or an edible oil or a mixture of edible oils preferably with omega- 3 -fatty acid content
  • the synergy can be the result of the use of prebiotics, probiotics, phytosterols and derivatives, various plant extracts and powders, edible plant oils and their diglyceride and monoglyceride counterparts, lecithins, amino acids and minerals in supramolecular structures.
  • These supramolecular structures positively influence their stability and transport properties.
  • This supramolecular arrangement represents new qualities of the original components and further corroborates their useful bioactivities by modified solubility, transport and stability in these supramolecular assemblies.
  • a further embodiment of the present invention are the cases when these compositions incorporate further components belonging to the group of vitamins. Due to the special process, these vitamins can be both water soluble and water insoluble. This allows us to employ vitamins that can exert their own action and they can also corroborate the actions of the aforementioned prebiotic components and also those of the phytosterols. A very important contribution of these vitamin mixtures can be that of their antioxidant properties.
  • a further embodiment of the present invention is the incorporation of physiologically important elements and trace elements that include but are not limited to calcium, magnesium, zinc, phosphorus, selenium, boron, chromium, copper, potassium, iodine, indium and other useful trace elements.
  • compositions according to the present invention can be characterized in that in addition to the discussed prebiotics and phytosterols and lecithins the said further plant extracts or powders are one or more of those of Panax ginseng (red, Korean ginseng), Panax ginseng (white, Chinese ginseng), Rhodiola rosea (golden root), Panax quinquefolium (American ginseng), Eleutherococcus senticosus (Siberian ginseng), Cynara scolymus (artichoke), Uncaria tomentosa (Cat's claw), Lepidium meyenii (maca, Peruvian ginseng), Paullinia cupana (guarana), Croton lechleri (Sangre de Grado), Whitania somnifera (ashwagandha, Indian ginseng), Panax japonicus (
  • plant extracts and plant powders are capable to potentiate the bioactivity of these compositions based on prebiotics, phytosterols, lecithins, vitamins and minerals. In given cases it also adds other prebiotics to the aforementioned prebiotic mixtures. These can result in more pronounced bioactivities as prebiotics and also in the chosen other bioactivity directions.
  • a further embodiment of the present invention is the ester scrambling method for the edible oil/phytosterol or edible oil/phytosterol/lecithin systems.
  • the heat treatment allows the scrambling and exchange of ester groups between the triglicerides, the lecithins and the originally unesterified or esterified phytosterols. This corroborates the bioavailability and transport of the components involved.
  • a further embodiment of our present invention is the use of probiotics to obtain synbiotic compositions wherein to the compositions described earlier one or more probiotic strains of bacteria are added.
  • This allows the formation of synbiotic compositions containing both prebiotic and probiotic elements.
  • These compositions allow the selective food support of the already colonized intestinal bacteria as well as novel probiotics for colonizing mainly the large intestine (colon) and also supplying beneficial planktonic bacteria for the gastrointestinal system.
  • the probiotic bacteria can be omitted or employed depending on the desired end-use of the compositions.
  • a further embodiment of our invention is the application of the method for the formation of compositions by spontaneous multicomponent supramolecular self- assembly for the preparation of cosmetics.
  • the oils are employed individually or in a mixture of the following oils or butters: ostrich oil, evening primrose oil, jojoba oil, macadamia nut oil, shea butter, avocado oil, grapeseed oil, tamanu oil, rose hips oil, pomegranate oil, papaya seed oil, moringa oil, mango butter, argan oil, blackcurrant oil, almond oil, apricot kernel oil, borage oil, coconut oil, hazelnut oil, hemp seed oil, neem oil, olive oil, peach kernel oil, sesame oil, wheatgerm oil.
  • compositions according to the invention are prepared in several forms that include beverages as well as solid medicaments, dietary supplements, food additives and foods, as well as cosmetics in various gel forms.
  • a further embodiment of this invention are cosmetic compositions with the usual skin- care and hair-care additives.
  • a further embodiment of present invention is pharmaceutical compositions. These pharmaceutical compositions can be prepared in the form of tablets, controlled release tablets, chewing tablets, enteric coated tablets, mucoadhesive vaginal tablets, capsules, gels, sols, solutions, tinctures, sprays, plasters, depending on the proposed application. In a typical embodiment of pharmaceutical compositions tablets are pressed.
  • the active components are formulated together with diluents, excipients or carriers and disintegrants, selected from calcium carbonate, silicium dioxide, magnesium stearate, and fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, calcium carbonate, and sodium citrate), low substituted hydroxypropylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose, calcium carboxymethyl cellulose and croscarmellose sodium.
  • the composition also contains extra-granular components comprising silicon dioxide and a lubricant.
  • Mucoadhesive vaginal tablets can also be prepared from the basic compositions by directly compressing the natural chitosan, cross-linked with glutaraldehyde and if desired with sodium alginate, together with microcrystalline cellulose, sodium carboxymethylcellulose or the hydrophilic (hydroxypropyl methylcellulose [HPMC]).
  • Dietary supplements can also be prepared according to our invention comprising the prebiotic compositions with the usual nutritionally acceptable additives.
  • prebiotic or synbiotic beverages that contain our prebiotic compositions together with natural fruit juices or other fluids, including dairy or non-dairy products with the usual nutritionally acceptable additives (sweeteners, acidulants, aromas, colorants).
  • a further embodiment of our invention are food items including prebiotic, probiotic or synbiotic hamburger, cheeseburger, pizza or other fast food. Due to the thermal stability of our compositions, any of these can be applied to the preparation of the hamburger buns and/or the hamburger meat.
  • the probiotic component can be applied in the cheese or in the dressing.
  • a typical burger according to our invention may contain 50% to 100% of the suggested daily dose of prebiotics, phytosterols, probiotics, certain vitamins and minerals.
  • a prebiotic burger with a probiotic cheese or a probiotic dressing is a synbiotic food item (health food).
  • a phytosterol mixture (soy origin) (10 g) is heated with corn oil (20 g) for 2 hours at 100 0 C. Depending on the components a solid acid or other catalyst can be used. Then the mixture is cooled to 20 0 C and added upon stirring into a mixture of lecithin (2Og, soy origin), water (20 ml) and L-lysine (10 g). Finally, this mixture is further mixed with 100 g prebiotic carbohydrates (8O g inulin, 1O g galacto-oligosaccharide, 8 g fructo-oligosaccharide and 2 g lactulose). Depending on the anticipated end-use, further components can be added that may include plant extracts and plant powders, vitamins, minerals, antioxidants and the usual fillers, stabilizers, adhesion modifiers.
  • Example 1 corn germ oil is used.
  • Example 4 The method is followed described in Example 1 but corn fiber oil is used. Example 4
  • Example 1 The method is followed described in Example 1 but fish oil is used.
  • the prebiotic mixture is 80 g of prebiotic carbohydrates (60 g inulin, 1O g beta-glucan, 8 g Aloe vera gel powder and 2 g tagatose).
  • salt NaCl
  • a baking mix, described in Example 12 is added (125 g), followed by water (0.3 to 0.4 liter) and the mixture thus obtained is kneaded into a dough.
  • the amount of water depends on the flour or flour mix used.
  • the dough is then processed and baked in an owen.
  • the dough is the prebiotic and the filling, applied after baking is the probiotic component.
  • the dough is made by the use of any of the compositions described in Examples 1 to 11.
  • flour (380 g), composition according to Example 1 (120 g), dry yeast (20 g), sugar (25 g), lemon peel (grated, 30 g), eggs (2), margarine (50 g), milk
  • Example 15 (200 ml) is used to make a dough. This dough is levened, fried in 12 pieces in hot oil and filled (after cooling) with a cream containing the probiotic bacteria.
  • This premix can be used in various fodder and dry feed mixtures.
  • compositions described in Examples 1 to 11 is mixed with a proprietary composition of extracts of the following herbs and plants (20 g): Panax ginseng (red, Korean ginseng), Panax ginseng (white, Chinese ginseng), Rhodiola rosea (golden root), Panax quinquefolium (American ginseng), Eleutherococcus senticosus (Siberian ginseng), Cynara scolymus (artichoke), Uncaria tomentosa (Cat's claw), Lepidium meyenii (maca, Peruvian ginseng), Paullinia cupana (guarana), Croton lechleri (Sangre de Grado), Whitania somnifera (ashwagandha, Indian ginseng), Astragalus memhranaceus (astragalus), Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (Pau d'arco), Echin
  • oils or butters ostrich oil, evening primrose oil, jojoba oil, macadamia nut oil, shea butter, avocado oil, grapeseed oil, tamanu oil, rose hips oil, pomegranate oil, papaya seed oil, moringa oil, mango butter, argan oil, blackcurrant oil, almond oil, apricot kernel oil, borage oil, coconut oil, hazelnut oil, hemp seed oil, neem oil, olive oil, peach kernel oil, sesame oil, wheatgerm oil.
  • oils or butters ostrich oil, evening primrose oil, jojoba oil, macadamia nut oil, shea butter, avocado oil, grapeseed oil, tamanu oil, rose hips oil, pomegranate oil, papaya seed oil, moringa oil, mango butter, argan oil, blackcurrant oil, almond oil, apricot kernel oil, borage oil, coconut oil, hazelnut oil, hemp seed oil, neem oil, olive oil
  • compositions of Examples 1 to 11, Example 16 and Example 17 in 20 %, sodium carboxymethylcellulose 26%, sodium alginate 22%, micro crystalline cellulose 23%, hydroxypropyl methylcellulose [HPMC] 3% and chitosan 6%.
  • Cosmetic composition containing one of the prebiotic compositions of Examples 1 to 11, Example 16 and Example 17 with the usual skin-care and hair-care additives. These compositions can be applied in the typical cosmetic bases usually in 1% to 90%.
  • a typical application in moisturizing cream a composition descibed in Example 1 applied in the following manner: prebiotic composition 10 part, propylene glycol 4.0 part, methyl paraben 0.2 part, water 60.0 part, triefhanolamine 2.0 part glyceryl sterate and PEG 6.0 part, stearate/stearic acid 6.0 part, cetyl alcohol 1.0 part, isopropyl myristate 15.0 part, propyl paraben 0.1 part, dimethicone 1.0 part, fragrance, coloring.
  • 180 g of the prebiotic composition described in Example 1 was mixed with a proprietary mixture (100 g) of Cordyceps sinensis (Cordycaps), Lentinula edodes (Shitake), Ganoderma lucidium (Reishi), Grifola frondosa (maitake), Tremella fuciformis (Silver ear), Poria cocos (Hoelen), Hericium erinaceus (Lion's Mane), Agaricus blazei (Sun mushroom), Phellinus linteus (Mulberry yellow polypore), Trametes versicolor, Coriolus versicolor (Turkey tails), Schizophyllum commune (Split gill), Inonotus obliquus (Cinder conk), oat bran, rice bran extracts and powders.
  • Example 11 Beverage containing one of the prebiotic compositions of Examples 1 to 11, Example 16 and Example 17 with natural fruit juices or other fluids, including dairy or non-dairy products with the usual nutritionally acceptable additives.
  • the prebiotic composition described in Example 11 160 g was mixed with a proprietary mixture (5 g) of Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (P au d'arco), Echinacea purpurea, Peumus boldus (boldo), Gynostemma pentaphyllum (Jiaogulan, also known as Southern Ginseng or Xiancao), Sutherlandia frutescens (African ginseng), Aloe vera (aloe), Cistanche salsa, Cistanche deserticola.
  • the components were thoroughly mixed. A portion of this powder mixture (82.5 g) was added to 0.9 liter of orange juice with pulp. The final volume was corrected to
  • compositions described in Examples 1 to 11 can be applied in the preparation of the hamburger bun and/or the hamburger meat.
  • one hamburger bun or one hamburger contains 8 g of the composition described in Example 1.
  • the probiotic component can be applied in cheese or dressing.
  • a prebiotic burger with a probiotic dressing is a synbiotic food item (health food).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofractoses, fructo-oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.

Description

SYNERGISTIC PREBIOTIC COMPOSITIONS
The present invention relates to synergistic prebiotic compositions in which fructose polymers of GFn or Fm structures, either containing a glucose (G) end-group and one or more prebiotic components from a group of prebiotics consisting of modified or unmodified starch and suitable partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fructo-oligosacharides (FOS), lactulose, galactomannan and suitable hydrolysates thereof, indigestible polydextrose, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), acemannan, lentinan or beta-glucan and partial hydrolysates thereof, polysaccharides P and K (PSP, PSK), tagatose and if desired phytosterols and lecithins are used, optionally with other plant extracts or dried plant powders, mineral components vitamins, amino acids and other additives.
Prebiotics are in most cases oligo- and/or polysaccharides that are not digested in the stomach and small intestine and reach the colon more or less intact (Roberfroid MB. Prebiotics: preferential substrates for specific germs? American Journal of Clinical Nutrition, 2001 :73(2) 406S-409S). However, colonic bacteria are able to use these compounds (Macfarlane GT, Gibson GR. Metabolic activities of the normal colonic flora. In: Gibson SAW, ed. Human health - the contribution of microorganisms. London: Springer- Verlag, 1994:17-52). The advantageous prebiotic components are capable to increase the amount of probiotic microorganisms in the colonic microflora (Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut, American Journal of Clinical Nutrition, 1999:69(5), 1052S-1057S). Together with probiotics-related or independent effects said compositions exert a complex physiological influence in the host (Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004:20(2): 146-155). These include the positive change in lipid and cholesterol levels, limiting the occurrence and amount of dangerous or disadvantegous resident bacteria (these include the dangerous Helicobacter pylori or Clostridia) or invading colonic bacteria (Aim L. The effect of Lactobacillus acidophilus administration upon survival of Salmonella in randomly selected human carriers. Prog Food Nutr Sci 1983:7:13-7; Gibson GR, Wang X. Regulatory effects of bifidobacteria on other colonic bacteria. J Appl Bacteriol 1994;77:412-20). The said compositions can thereby reduce the risk of the leading causes of death, (Functional Foods, G. R. Gibson, C. M. Williams, eds., 389. pp., Woodhead Publishing Ltd, Abington Hall, Abington, Cambridge, England, 2000/2002) heart and circulatory diseases and colorectal (Reddy BS, Hamid R, Rao CV. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. 1997: Carcinogenesis 18:1371- 1374) or other cancer (Van Loo J, Clune Y, Bennett M, Collins JK. The SYNCAN project : goals, set-up, first results and settings of the human dietary intervention study. 2005:Brit. J. Nutr. 93(Sl), 91-98). Interestingly, the anticancer properties of prebiotics are not limited to colonic events (Taper HS, Roberfroid M. Influence of inulin and oligofructose on breast cancer and tumor growth. J. Nutr. 1999: 129: 1488S-1491S. ) An important part of human nutrition is the consumption of suitable amount of soluble and insoluble fiber. It is known from the literature that it is possible to influence and change the colonic microflora thereby improving the health of the host. The prebiotic- probiotic-synbiotic concept is a clear demostration of these effects (Bengmark S. Pre-, pro- and synbiotics. Current Opinion in Clinical Nutrition and Metabolic Care 2001 :4(6):571-579; Bengmark S. Gut microbial ecology in critical illness: is there a role for pre-, pro-, and synbiotics. Current Opinion in Critical Care, 2002: 8: 2). The gastro-intestinal system of a fetus is sterile. The colonization starts during and after birth and the formation of the complex colonic microflora proceeds for years. In fact, the colonic microflora is a changeable biodynamic ecosystem. By the age of two years, the colon of a child is colonized with a hundred or a couple of hundreds strains of bacteria. This develops further and the colonic microflora then remains a close-knit commensal bacterial ecosystem until the age of about 60 years. After that this systems gets somewhat loose, allowing new (unwanted) members to get attached to the system. This contributes or may contribute to the decline of health of the elderly people. The microbes in the colon (colonized and planktonic) are capable to exert the following positive effects:
- Suppressing the dangerous colonic microorganisms (invading or colonized) and thereby the production of some of their potentially carcinogenic metabolism products and certain unwanted enzymes).
- Prevention of the colon from attack of dangerous exogenous microorganisms.
- Increase of the ratio of the advantageous probiotic bacteria both in the small intestine and also in the colon.
- Improving the developing colonic microflora of the newborn.
- Prevention of the outbreak and reducing the severity of the symptoms of diarrhoea caused by rotaviruses and other viruses and bacteria.
- Reducing the symptoms of chronic intestinal inflammations (Crohn-disease, IBS, colitis).
- Production of short-chain fatty acids (SCF). Production of lactic acid.
- Influence on bile-acid transport and biochemical transformations thereof.
- Partial inhibition of hepatic cholesterol biosynthesis.
- Modulation of insulin production and activity.
- Providing extra food for the colonocytes.
- Regulating the production of immunoglobulins and secretory IgA.
- Suppression of the formation of aberrant crypt foci and further steps of colorectal carcinogenesis. - Suppression of cancer-causing potential of external chemical carcinogenes.
- Suppression of clostridial formation of potentially carcinogenic secondary bile acids.
- Suppression of allergies (including atopic dermatitis).
- Reducing the symptoms of lactose intolerance and other food allergies.
- Reducing the pH of the colon, thereby making the conditions less suitable for certain pathogens.
- Increasing bowel motility.
- Increasing calcium uptake.
These processes, through various biochemical and physiological pathways, exert a generally advantageous physiological action for the host (in this case the human body). It is noteworthy, however, that said positive physiological effects can also be useful for animals. Therefore, the compositions can also be utilized in fodder and feed additives (Abe F, Ishibashi N, Shimamura S. Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets. J. Dairy Sci. 1995:78:2838-2846.). In addition to the bioactivity discussed above, said compositions are capable to reduce symptoms of allergy (Noverr MC, Hufmagle GB. Does the microbiota regulate immune responses outside the gut? Trends in Microbiology 2004:12:562-568). Said compositions are able to positively modulate the immune system (Gut Flora, Nutrition and Immunity, Fuller R., Perdigόn G., Eds., Blackwell Publishing, 2003).
It is well documented in the literature that phytosterols as well as their hydrogenated counterparts, phytostanols and their esters are capable to reduce the total cholesterol and low density lipoprotein cholesterol (LDL) levels in the human blood. Consumption of plant sterols, however, is not a new phenomenon. In fact, it precedes that of the human development. Our close relative primates continue to consume a much higher amount of phytosterols daily than the modern man. The typically 100 to 300 mg/day plant sterol consumption of humans today is much less than the amount required to achieve a meaningful change in blood lipid parameters.
The effect is complex. It is achieved by the phytosterol inhibition of the absorption of the exogenous (food) cholesterol and also by the inhibition of the reabsorption of the cholesterol transported by the endogenous enterohepatic circulation. These result in increased cholesterol clearance. The cholesterol and phytosterol transport can be modulated by the application of plant sterols in lecithin micelles (Ostlund RE, Jr., Spilburg CA, Stenson WF. Sitostanol administered in lecithin micelles potentially reduces cholesterol absorption in humans. American Journal of Clinical Nutrition, 1999:70:826-831). Phytosterols are also capable to prevent the development of benign prostatic hyperplasia (BPH) (Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83:976-983). The successful and efficient application of phytosterol esters in bakery products for the reduction of plasma LDL-cholesterol has also been documented (Quilez J, Rafecas M, Brufau G, Garcia-Lorda P, Megias I, Bullό M, Ruiz JA, Salas-Salvado J, J. Nutr. 2003:133:3103-3109 and references there cited).
We have found that a proper combination of prebiotics may exert a synergistic effect. The compositions comprising the combination according to the present invention may be used as medicaments, cosmetics, food and fodder additives, dietary supplements, as well as prebiotic and symbiotic food and fodder.
The present invention relates to synergistic prebiotic compositions comprising prebiotic components selected from fructose polymers GFn and Fmj either containing a glucose (G) end-group, or without this glucose end-group and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fructo- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.
Preferably, the compositions according to the present invention comprise prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without this glucose end-group and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed . inulin, natural oligofructoses, fructo- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo- oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives. The fructose polymers OfGFn or Fm structures (G= glucose; F= fructose; n>2; m>2) are linear fructose polymers having either a glucose (G) and-group, or being without this glucose and-group. Oligofructoses are consisted of 3 to 10 carbohydrate units. Above that, chicory inulin contains 10 to 60 carbohydrate units, typically with 27 carbohydrates (fructoses with our without one glucose end-group and a fructose chain). Other plants may produce different fructans. These fructans are capable to increase the number of colonized and planktonic bacteria in the larges intestine. This results in a change that those bacteria that are less advantageous or may turn dangerous are suppressed by the higher probiotic colony of bacteria. Depending on the chain length of these fractans or other prebiotics, they can be fermented by probiotic bacteria at different positions in the colon. We have found that the longer inulins are capable to rich the distal colon and sigmoid colon and exert their anticancer actions in the positions where typically most of the canerous problems occur. The occurrence of these cancers can be the result of various types of carcinogenesis. It has been demonstrated in the literature that directly induced chemical carcinogenesis can be greatly reduced by probiotic bacteria. The prebiotic compositions of our invention can corroborate this effect by considerably increasing the number of Bifidocateria and other beneficial probiotic strains. The local chemical carcinogenesis can also be the result of the formation of secondary bile acids. These secondary bile acids are often formed upon the action of enzymes produced by resident Clostridia. By probiotic supression of the number of these bacteria according to the invention, the chance of secondary bile acid formation can also be reduced. This can be demonstrated by measuring the faecal primary/secondary bile acid ratio.
Other prebiotics can be selected from a group of prebiotics consisting of various gums (guar gum, xanthan gum, locust been gum), carob seed flour, oat bran, rice bran, barley, modified or unmodified starch and suitable partial hydrolysates thereof, partially hydrolysed inulin, natural or synthetic/biosynthetic oligofructoses, fructo- oligosacharides (FOS), lactulose, galactomannan and suitable hydrolysates thereof, indigestible polydextrose, indigestible dextrin and partial hydrolysates thereof, trans- galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), acemannan, lentinan or beta-glucan and partial hydrolysates thereof, polysaccharides P and K (PSP, PSK), tagatose, various fungal oligosaccharides and polysaccharides, together with other components. Further embodiment of the invention is the application of various phytosterols in these compositions. These phytosterols can be found in various plants. Typically the mixture of phytosterols used in foods are of soy or tall oil origin. Corn fiber oil is also very rich in phytosterols and their derivatives. It is well documented in the scientific literature that a considerable reduction (10-20%) of low density lipoprotein (LDL) and total cholesterol (TC) can be achieved by suitable administration of these phytosterol mixtures, their reduced (phytostanol) counterparts and the corresponding phytosterol and phytostanol esters. It has also been demonstrated that the sterols and stanols on the one hand and their esterified counterparts on the other are all suitable for this purpose. The question remains whether these compounds are soluble in the media of applications.
A further embodiment of this invention is the formation of supramolecular compositions. In this process a spontaneous multicomponent supramolecular self- assembly (SMSA) takes place between the components (Jean-Marie Lehn, Perspectives in supramolecular chemistry: From molecular recognition towards self-organisation. Pure and Applied Chemistry 1994:66:1961-1966). To corroborate this self-assembly, we add lecithins and/or an edible oil or a mixture of edible oils, preferably with omega- 3 -fatty acid content during the preparation of these compositions. This results in improved solubility profile of the composition compared to the starting components. We have observed that the synergic effect of our compositions is achieved not only by the joint application of various prebiotics. In certain cases the synergy can be the result of the use of prebiotics, probiotics, phytosterols and derivatives, various plant extracts and powders, edible plant oils and their diglyceride and monoglyceride counterparts, lecithins, amino acids and minerals in supramolecular structures. These supramolecular structures positively influence their stability and transport properties. This supramolecular arrangement represents new qualities of the original components and further corroborates their useful bioactivities by modified solubility, transport and stability in these supramolecular assemblies.
A further embodiment of the present invention are the cases when these compositions incorporate further components belonging to the group of vitamins. Due to the special process, these vitamins can be both water soluble and water insoluble. This allows us to employ vitamins that can exert their own action and they can also corroborate the actions of the aforementioned prebiotic components and also those of the phytosterols. A very important contribution of these vitamin mixtures can be that of their antioxidant properties.
A further embodiment of the present invention is the incorporation of physiologically important elements and trace elements that include but are not limited to calcium, magnesium, zinc, phosphorus, selenium, boron, chromium, copper, potassium, iodine, indium and other useful trace elements.
In a further embodiment of the present invention various extracts and plant powders are incorporated into our compositions, depending on the desired properties according to the end use of said compositions. These compositions according to the present invention can be characterized in that in addition to the discussed prebiotics and phytosterols and lecithins the said further plant extracts or powders are one or more of those of Panax ginseng (red, Korean ginseng), Panax ginseng (white, Chinese ginseng), Rhodiola rosea (golden root), Panax quinquefolium (American ginseng), Eleutherococcus senticosus (Siberian ginseng), Cynara scolymus (artichoke), Uncaria tomentosa (Cat's claw), Lepidium meyenii (maca, Peruvian ginseng), Paullinia cupana (guarana), Croton lechleri (Sangre de Grado), Whitania somnifera (ashwagandha, Indian ginseng), Panax japonicus (Japanese ginseng), Panax vietnamensis (Vietnamese ginseng), Panax trifolius, Panax pseudoginseng, Panax notoginseng, Malpighia glabra (acerola), Ylex paraguayiensis (Yerba mate), Astragalus membranaceus (astragalus), Stevia rebaudiana (stevia), Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (Pau d'arco), Echinacea purpurea, Peumus boldus (boldo), Gynostemma pentaphyllum (Jiaogulan, also known as Southern Ginseng or Xiancao), Sutherlandia frutescens (African ginseng), Aloe vera (aloe), Cistanche salsa, Cistanche deserticola (and other Cistanche sp.), Codonopsis pilosula ("poor man's ginseng."), Nopal opuntia (Prickly pear cactus), Citrus sinensis (Citrus aurantium) and other members of the citrus family (lemon, lime, tangerine, grapefruit), Camelia sinensis (tea), Plantago psyllium (psyllium), Amaranth edulis and other amaranth sp. (amaranth), Commiphora mukul (guggul lipid), Serenoa repens, Serenoa serrulata (saw palmetto), Cordyceps sinensis (Cordycaps), Lentinula edodes (Shitake), Ganoderma lucidium (Reishi), Grifola frondosa (maitake), , Tremella fuciformis (Silver ear), Poria cocos (Hoelen), Hericium erinaceus (Lion's Mane), Agaricus blazei (Sun mushroom), Phellinus linteus (Mulberry yellow polypore), Trametes versicolor, Coriolus versicolor (Turkey tails), Schizophyllum commune (Split gill), Inonotus obliquus (Cinder conic), oat bran, rice bran, linseed, garlic, Ceratonia siliqua (locust been gum or flour from the seeds of carob tree), Cyanopsis tetragonoloba (guar gum, EU Food additive code E412), Xanthomonas campestris (xanthan gum). These plant extracts and plant powders are capable to potentiate the bioactivity of these compositions based on prebiotics, phytosterols, lecithins, vitamins and minerals. In given cases it also adds other prebiotics to the aforementioned prebiotic mixtures. These can result in more pronounced bioactivities as prebiotics and also in the chosen other bioactivity directions.
A further embodiment of the present invention is the ester scrambling method for the edible oil/phytosterol or edible oil/phytosterol/lecithin systems. In this reaction the heat treatment (with catalysis) allows the scrambling and exchange of ester groups between the triglicerides, the lecithins and the originally unesterified or esterified phytosterols. This corroborates the bioavailability and transport of the components involved.
A further embodiment of our present invention is the use of probiotics to obtain synbiotic compositions wherein to the compositions described earlier one or more probiotic strains of bacteria are added. This allows the formation of synbiotic compositions containing both prebiotic and probiotic elements. These compositions allow the selective food support of the already colonized intestinal bacteria as well as novel probiotics for colonizing mainly the large intestine (colon) and also supplying beneficial planktonic bacteria for the gastrointestinal system. The probiotic bacteria can be omitted or employed depending on the desired end-use of the compositions.
A further embodiment of our invention is the application of the method for the formation of compositions by spontaneous multicomponent supramolecular self- assembly for the preparation of cosmetics. The oils are employed individually or in a mixture of the following oils or butters: ostrich oil, evening primrose oil, jojoba oil, macadamia nut oil, shea butter, avocado oil, grapeseed oil, tamanu oil, rose hips oil, pomegranate oil, papaya seed oil, moringa oil, mango butter, argan oil, blackcurrant oil, almond oil, apricot kernel oil, borage oil, coconut oil, hazelnut oil, hemp seed oil, neem oil, olive oil, peach kernel oil, sesame oil, wheatgerm oil.
The compositions according to the invention are prepared in several forms that include beverages as well as solid medicaments, dietary supplements, food additives and foods, as well as cosmetics in various gel forms.
A further embodiment of this invention are cosmetic compositions with the usual skin- care and hair-care additives. A further embodiment of present invention is pharmaceutical compositions. These pharmaceutical compositions can be prepared in the form of tablets, controlled release tablets, chewing tablets, enteric coated tablets, mucoadhesive vaginal tablets, capsules, gels, sols, solutions, tinctures, sprays, plasters, depending on the proposed application. In a typical embodiment of pharmaceutical compositions tablets are pressed. In these tablet form pharmaceutical preparations the active components are formulated together with diluents, excipients or carriers and disintegrants, selected from calcium carbonate, silicium dioxide, magnesium stearate, and fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, calcium carbonate, and sodium citrate), low substituted hydroxypropylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose, calcium carboxymethyl cellulose and croscarmellose sodium. Preferably, the composition also contains extra-granular components comprising silicon dioxide and a lubricant.
Mucoadhesive vaginal tablets can also be prepared from the basic compositions by directly compressing the natural chitosan, cross-linked with glutaraldehyde and if desired with sodium alginate, together with microcrystalline cellulose, sodium carboxymethylcellulose or the hydrophilic (hydroxypropyl methylcellulose [HPMC]).
Dietary supplements can also be prepared according to our invention comprising the prebiotic compositions with the usual nutritionally acceptable additives.
Further embodiment of our invention are prebiotic or synbiotic beverages that contain our prebiotic compositions together with natural fruit juices or other fluids, including dairy or non-dairy products with the usual nutritionally acceptable additives (sweeteners, acidulants, aromas, colorants).
A further embodiment of our invention are food items including prebiotic, probiotic or synbiotic hamburger, cheeseburger, pizza or other fast food. Due to the thermal stability of our compositions, any of these can be applied to the preparation of the hamburger buns and/or the hamburger meat. The probiotic component can be applied in the cheese or in the dressing. A typical burger according to our invention may contain 50% to 100% of the suggested daily dose of prebiotics, phytosterols, probiotics, certain vitamins and minerals. A prebiotic burger with a probiotic cheese or a probiotic dressing is a synbiotic food item (health food).
The following examples are given as illustrations only of the said invention and in no way should be construed as limiting the subject matter of the present invention.
Example 1
A phytosterol mixture (soy origin) (10 g) is heated with corn oil (20 g) for 2 hours at 100 0C. Depending on the components a solid acid or other catalyst can be used. Then the mixture is cooled to 20 0C and added upon stirring into a mixture of lecithin (2Og, soy origin), water (20 ml) and L-lysine (10 g). Finally, this mixture is further mixed with 100 g prebiotic carbohydrates (8O g inulin, 1O g galacto-oligosaccharide, 8 g fructo-oligosaccharide and 2 g lactulose). Depending on the anticipated end-use, further components can be added that may include plant extracts and plant powders, vitamins, minerals, antioxidants and the usual fillers, stabilizers, adhesion modifiers.
Example 2
The method is followed described in Example 1 but corn germ oil is used.
Example 3
The method is followed described in Example 1 but corn fiber oil is used. Example 4
The method is followed described in Example 1 but coconut oil is used.
Example 5
The method is followed described in Example 1 but pumpkinseed oil is used.
Example 6
The method is followed described in Example 1 but fish oil is used.
Example 7
The method is followed described in Example 1 but other edible oils or their mixtures are used.
Example 8
The method is followed described in Examples 1 to 7 but sunflower seed lecithin is used.
Example 9
The method is followed described in Examples 1 to 7 but egg lecithin is used.
Example 10
The method is followed described in Examples 1 to 9 but a tall oil phytosterol mixture is used. Example 11
The method is followed described in examples 1 to 10 but the prebiotic mixture is 80 g of prebiotic carbohydrates (60 g inulin, 1O g beta-glucan, 8 g Aloe vera gel powder and 2 g tagatose).
Example 12
Food additive (baking mix)
To any of the basic compositions described in Examples 1-11, salt (NaCl) is added
(50 g), followed by ascorbic acid (200 mg), a multivitamin mixture (1 g) and dry instant yeast (20 g) and the mixture thus obtained is thoroughly homogenized.
Example 13
Probiotic bakery product (bread)
To the baking flour or flour mixture (700 g) a baking mix, described in Example 12 is added (125 g), followed by water (0.3 to 0.4 liter) and the mixture thus obtained is kneaded into a dough. The amount of water depends on the flour or flour mix used.
The dough is then processed and baked in an owen.
Example 14
Synbiotic product (pastry)
In this product the dough is the prebiotic and the filling, applied after baking is the probiotic component. The dough is made by the use of any of the compositions described in Examples 1 to 11.
In a typical application, flour (380 g), composition according to Example 1 (120 g), dry yeast (20 g), sugar (25 g), lemon peel (grated, 30 g), eggs (2), margarine (50 g), milk
(200 ml) is used to make a dough. This dough is levened, fried in 12 pieces in hot oil and filled (after cooling) with a cream containing the probiotic bacteria. Example 15
Dry feed additive
Any of the compositions described in Examples 1 to 11 is mixed with milled cereals
(1 to 5 kg) and to this mixture oily seed industrial byproducts are added to obtain a mixture of 10 kg. This premix can be used in various fodder and dry feed mixtures.
Example 16
Any of the compositions described in Examples 1 to 11 is mixed with a proprietary composition of extracts of the following herbs and plants (20 g): Panax ginseng (red, Korean ginseng), Panax ginseng (white, Chinese ginseng), Rhodiola rosea (golden root), Panax quinquefolium (American ginseng), Eleutherococcus senticosus (Siberian ginseng), Cynara scolymus (artichoke), Uncaria tomentosa (Cat's claw), Lepidium meyenii (maca, Peruvian ginseng), Paullinia cupana (guarana), Croton lechleri (Sangre de Grado), Whitania somnifera (ashwagandha, Indian ginseng), Astragalus memhranaceus (astragalus), Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (Pau d'arco), Echinacea purpurea, Peumus boldus (boldo), Gynostemma pentaphyllum (Jiaogulan, also known as Southern Ginseng or Xiancao), Sutherlandia frutescens (African ginseng), Aloe vera (aloe), Cistanche salsa, Cistanche deserticola, Codonopsis pilosula.
Example 17
The method is followed described in examples 1 to 11 but the oil employed is individually or in a mixture of the following oils or butters: ostrich oil, evening primrose oil, jojoba oil, macadamia nut oil, shea butter, avocado oil, grapeseed oil, tamanu oil, rose hips oil, pomegranate oil, papaya seed oil, moringa oil, mango butter, argan oil, blackcurrant oil, almond oil, apricot kernel oil, borage oil, coconut oil, hazelnut oil, hemp seed oil, neem oil, olive oil, peach kernel oil, sesame oil, wheatgerm oil. These compositions can be applied in the typical cosmetic bases in 1 to 90%.
Example 18
Pharmaceutical preparation containing one of the compositions of Examples 1 to 11, Example 16 and Example 17 in 20 %, sodium carboxymethylcellulose 26%, sodium alginate 22%, micro crystalline cellulose 23%, hydroxypropyl methylcellulose [HPMC] 3% and chitosan 6%.
Example 19
Cosmetic composition containing one of the prebiotic compositions of Examples 1 to 11, Example 16 and Example 17 with the usual skin-care and hair-care additives. These compositions can be applied in the typical cosmetic bases usually in 1% to 90%. A typical application in moisturizing cream a composition descibed in Example 1 applied in the following manner: prebiotic composition 10 part, propylene glycol 4.0 part, methyl paraben 0.2 part, water 60.0 part, triefhanolamine 2.0 part glyceryl sterate and PEG 6.0 part, stearate/stearic acid 6.0 part, cetyl alcohol 1.0 part, isopropyl myristate 15.0 part, propyl paraben 0.1 part, dimethicone 1.0 part, fragrance, coloring.
Example 20
Dietary supplement containing one of the prebiotic compositions of Examples 1 to 11, Example 16 and Example 17 with the usual nutritionally acceptable additives. In a typical embodiment of our invention 180 g of the prebiotic composition described in Example 1 was mixed with a proprietary mixture (100 g) of Cordyceps sinensis (Cordycaps), Lentinula edodes (Shitake), Ganoderma lucidium (Reishi), Grifola frondosa (maitake), Tremella fuciformis (Silver ear), Poria cocos (Hoelen), Hericium erinaceus (Lion's Mane), Agaricus blazei (Sun mushroom), Phellinus linteus (Mulberry yellow polypore), Trametes versicolor, Coriolus versicolor (Turkey tails), Schizophyllum commune (Split gill), Inonotus obliquus (Cinder conk), oat bran, rice bran extracts and powders. After thoroughly mixing the composition thus obtained was filled in capsules or in bottles as loose powder.
Example 21
Beverage containing one of the prebiotic compositions of Examples 1 to 11, Example 16 and Example 17 with natural fruit juices or other fluids, including dairy or non-dairy products with the usual nutritionally acceptable additives. In a typical application the prebiotic composition described in Example 11 (160 g) was mixed with a proprietary mixture (5 g) of Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (P au d'arco), Echinacea purpurea, Peumus boldus (boldo), Gynostemma pentaphyllum (Jiaogulan, also known as Southern Ginseng or Xiancao), Sutherlandia frutescens (African ginseng), Aloe vera (aloe), Cistanche salsa, Cistanche deserticola. The components were thoroughly mixed. A portion of this powder mixture (82.5 g) was added to 0.9 liter of orange juice with pulp. The final volume was corrected to 1 liter.
Example 22
Prebiotic, probiotic or synbiotic hamburger or other fast food
Any of the compositions described in Examples 1 to 11 can be applied in the preparation of the hamburger bun and/or the hamburger meat. In the preferred embodiment of the invention one hamburger bun or one hamburger contains 8 g of the composition described in Example 1. The probiotic component can be applied in cheese or dressing.
A prebiotic burger with a probiotic dressing is a synbiotic food item (health food).

Claims

1. Synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fructo- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto- oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.
2. Synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofructoses, fracto- oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto- oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral .components, vitamins and additives.
3. Compositions according to claims 1 and 2 characterized in that the said further plant extracts or powders are one or more of those of Panax ginseng (red, Korean ginseng), Panax ginseng (white, Chinese ginseng), Rhodiola rosea (golden root), Panax quinquefolium (American ginseng), Eleutherococcus senticosus (Siberian ginseng), Cynara scolymus (artichoke), Uncaria tomentosa (Cat's claw), Lepidium meyenii (maca, Peruvian ginseng), Paullinia cupana (guarana), Croton lechleri (Sangre de Grado), WIiitania somnifera (ashwagandha, Indian ginseng), Panax japonicus (Japanese ginseng), Panax vietnamensis (Vietnamese ginseng), Panax trifolius, Panax pseudoginseng, Panax notoginseng, Malpighia glabra (acerola), Ylex paraguayiensis (Yerba mate), Astragalus membranaceus (astragalus), Stevia rebaudiana (stevia), Pfaffia paniculata (Brazilian ginseng, suma), Ginkgo biloba, Tabebuia impetiginosa (Pau d'arco), Echinacea purpurea, Peumus boldus (boldo), Gynostemma pentaphyllum (Jiaogulan, also known as Southern Ginseng or Xiancao), Sutherlandia frutescens (African ginseng), Aloe vera (aloe), Cistanche salsa, Cistanche deserticola (and other Cistanche sp.), Codonopsis pilosula ("poor man's ginseng."), Nopal opuntia (Prickly pear cactus), Citrus sinensis {Citrus aurantium) and other members of the citrus family (lemon, lime, tangerine, grapefruit), Camelia sinensis (tea), Plantago psyllium (psyllium), Amaranth edulis and other amaranth sp. (amaranth), Commiphora mukul (guggul lipid), Serenoa repens, Serenoa serrulata (saw palmetto), Cordyceps sinensis (Cordycaps), Lentinula edodes (Shitake), Ganoderma lucidium (Reishi), Grifola frondosa (maitake), , Tremella fuciformis (Silver ear), Poria cocos (Hoelen), Hericium erinaceus (Lion's Mane), Agaricus blazei (Sun mushroom), Phellinus linteus (Mulberry yellow polypore), Trametes versicolor, Coriolus versicolor (Turkey tails), Schizophyllum commune (Split gill), Inonotus obliquus (Cinder conk), oat bran, rice bran, linseed, garlic, Ceratonia siliqua (locust been gum or flour from the seeds of carob tree), Cyanopsis tetragonoloba (guar gum, EU Food additive code E412), Xanthomonas campestris (xanthan gum).
4. A composition according to Claim 1 to 3 wherein the components are in a supramolecular arrangement.
5. A composition according to Claims 1 to 4 characterized in that the micelle forming components of the supramolecular arrangement are a mixture of natural lecithins.
6. A composition according to Claims 1 to 4 characterized in that the supramolecular arrangement is achieved in an oily phase.
7. A composition according to Claims 1 to 6 characterized in that the oily phase is an edible oil or a mixture of edible oils preferably with omega-3- fatty acid content.
8. A composition according to Claims 1 to 7 characterized in that one of the prebiotics is chicory inulin.
9. A composition according to Claims 1 to 8 characterized in that the phytosterol components are of soy, corn or tall oil origin or a pure phytosterol, or a mixture of any of these phytosterols, phytostanols or esters thereof.
10. A food product comprising a composition according to claims 1 to 9.
11. A beverage product comprising a composition according to Claims 1 to 9.
12. A nutritional or fodder additive preparation comprising a composition according to Claims 1-9.
13. A pharmaceutical preparation comprising a composition according to Claims 1 to 9 and usually applicable additives.
14. Use of the composition according to Claims 1 to 9 for the prevention or treatment of diseases, which may develop depending on the amount and nature of probiotic bacteria in the colonic or vaginal microflora.
15. Use of the composition according to Claims 1-9 characterized in that the said composition containing prebiotic components, phytosterols, lecithins and edible oils are applied for the change of lipid, and cholesterol and bile acid metabolism and transport, and blood lipid and cholesterol levels.
16. Use of the composition according to Claims 1-9 for the prevention of benign prostatic hyperplasia (BPH).
17. Use of the composition according to Claims 1-9 for developing and maintaining a healthy colonic and/or vaginal microflora.
18. Use of the composition according to Claims 1-9 for the prevention of gastrointestinal damage caused by therapy with oral antibiotics or other oral antibacterial agents.
19. Use of the composition according to Claims 1-9 wherein the prebiotic composition further comprises a probiotic thus providing a synbiotic preparation.
20. Use of the composition according to Claims 1-9 for the preparation of cosmetics.
21. Use of the composition according to Claims 10 and 11 as components of infant foπnula.
22. Use of the composition described in Claims 1-9 and to relieve or reduce symptoms of allergies.
23. Use of the composition according to Claims 1-9 for enhancing an immune response which comprises administering a composition in an amounts sufficient to enhance a detectable immune response.
24. Use of the composition according to Claims 1-9 to prevent or cure certain types of cancer.
25. Use of the composition according to Claims 1-9 to corroborate the effect of cholesterol lowering drugs.
26. Use of the composition according to Claims 1-9 to corroborate the effect of antibiotic or (synthetic) antibacterial therapy.
27. Use of the composition according to Claims 1-9 as immune modulants.
28. Methods for the preparation of compositions and products described in Examples 1 to 22.
PCT/HU2006/000051 2005-06-13 2006-06-12 Synergistic prebiotic compositions Ceased WO2006134409A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SI200632398T SI1893221T1 (en) 2005-06-13 2006-06-12 Synergistic prebiotic compositions
EP06744405.9A EP1893221B8 (en) 2005-06-13 2006-06-12 Synergistic prebiotic compositions
CA2611935A CA2611935C (en) 2005-06-13 2006-06-12 Synergistic prebiotic compositions
EA200800034A EA017289B1 (en) 2005-06-13 2006-06-12 SYNERGICAL PREBIOTIC COMPOSITION AND ITS APPLICATION
US11/917,236 US20080261916A1 (en) 2005-06-13 2006-06-12 Synergistic Prebiotic Compositions
US13/353,639 US20120121621A1 (en) 2005-06-13 2012-01-19 Synergistic prebiotic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0500582A HUP0500582A1 (en) 2005-06-13 2005-06-13 Foods food-additives and nutriment supplements or feed-additives with synergetic physiological effect
HUP0500582 2005-06-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/353,639 Division US20120121621A1 (en) 2005-06-13 2012-01-19 Synergistic prebiotic compositions

Publications (2)

Publication Number Publication Date
WO2006134409A2 true WO2006134409A2 (en) 2006-12-21
WO2006134409A3 WO2006134409A3 (en) 2007-03-01

Family

ID=89986079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2006/000051 Ceased WO2006134409A2 (en) 2005-06-13 2006-06-12 Synergistic prebiotic compositions

Country Status (7)

Country Link
US (2) US20080261916A1 (en)
EP (1) EP1893221B8 (en)
CA (1) CA2611935C (en)
EA (1) EA017289B1 (en)
HU (2) HUP0500582A1 (en)
SI (1) SI1893221T1 (en)
WO (1) WO2006134409A2 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080701A1 (en) * 2007-01-02 2008-07-10 Henkel Ag & Co. Kgaa Cosmetic compositions containing selected fatty acids and squalene
WO2008110399A1 (en) * 2007-03-14 2008-09-18 Unilever Plc Method of treating hair with a sugar composition
FR2916634A1 (en) * 2007-06-01 2008-12-05 Jean Noel Thorel Synergistic combination, useful e.g. as regulating agent of microbial flora of skin and to prepare cosmetic or pharmaceutical composition to treat oily or mixed skin, of fructo-oligosaccharides and inducer of antimicrobial peptide
EP2014181A3 (en) * 2007-06-15 2009-02-18 S.I.I.T. S.r.l. Servizio Internazionale Imballaggi Termosaldanti Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora
WO2009097885A1 (en) * 2008-02-05 2009-08-13 Unilever Plc Method of treating hair
GB2459121A (en) * 2008-04-10 2009-10-14 Prime Interaction Holdings Ltd A product for topical administration
FR2933848A1 (en) * 2008-07-18 2010-01-22 Roquette Freres COMPOSITION OF SOLUBLE INDIGESTIBLE FIBERS AND EUKARYOTIC ORGANISMS HAVING POLYSACCHARIDE WAVES USED IN THE WELL-BEING FIELD
FR2935228A1 (en) * 2009-09-30 2010-03-05 Roquette Freres Composition, useful e.g. for inducing the growth of the intestinal flora and treating or preventing e.g. cancer and chronic inflammatory bowel disease, comprises eukaryotic organisms with polysaccharide wall and branched maltodextrins
WO2010106384A1 (en) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Glucooligosaccharide nutraceutical, pharmaceutical, or food compositions
WO2010150051A1 (en) * 2009-06-24 2010-12-29 Lipoid Gmbh Composition for cosmetic, pharmaceutical or dietary applications
WO2011113501A1 (en) * 2010-03-15 2011-09-22 Henkel Ag & Co. Kgaa Hair treatment agent having at least four selected oils
US20120070521A1 (en) * 2009-05-22 2012-03-22 Bio-Ved Pharmaceuticals, PVT., Ltd. Method of extraction from withania somnifera and one or more fractions containing pharmacologically active ingredients obtained therefrom
US8187582B2 (en) 2008-03-28 2012-05-29 Conopco, Inc. Hair styling composition
US8192730B2 (en) 2004-03-08 2012-06-05 Conopco, Inc. Hair treatment composition comprising sugar lactone
EP2478779A1 (en) * 2011-01-24 2012-07-25 Biotechnobel Composition for providing beneficial health effects
DE102011012494A1 (en) 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotic carbohydrate compositions
CN102670729A (en) * 2012-05-16 2012-09-19 乌鲁木齐市生命核力高科有限公司 Preparation method for cistanche tubulosa and American ginseng compound capsule
US8273335B2 (en) 2007-10-10 2012-09-25 Conopco, Inc. Method of treating hair
CN101491668B (en) * 2008-01-23 2012-11-07 北京因科瑞斯医药科技有限公司 Composition with blood-sugar reducing function and preparation method thereof
ITRM20120084A1 (en) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola PREBIOTIC MIXTURE.
CN104105471A (en) * 2012-02-14 2014-10-15 宝洁公司 Topical use of skin-commensal prebiotic agent and compositions containing same
WO2015001175A1 (en) * 2013-07-05 2015-01-08 Raisio Nutrition Ltd Edible composition suitable for lowering serum cholesterol
WO2015136096A1 (en) * 2014-03-13 2015-09-17 Procare Health Iberia, S.L. Topical compositions comprising extract of coriolus versicolor for autoimmunity enhancement
CN105079777A (en) * 2015-08-05 2015-11-25 山东金城生物药业有限公司 Anti-oxidative and immunity-enhancing composition as well as preparation method and application thereof
CN105250437A (en) * 2015-11-17 2016-01-20 金平金岭生物瑶药开发有限责任公司 Yao bath powder special for gynecology
DE102015100923A1 (en) * 2014-08-07 2016-02-11 Mingfu LU Integrated nutritional powder and process for its preparation
CN105420119A (en) * 2015-12-14 2016-03-23 中国人民解放军第二军医大学 Ginseng endophytic fungus and application thereof
RU2579217C1 (en) * 2015-02-17 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный университет" (национальный исследовательский университет) (ФГБОУ ВПО "ЮУрГУ" (НИУ)) Enriched bakery product with antioxidant properties
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
ITUA20162240A1 (en) * 2016-04-13 2017-10-13 Maria Rosaria Ficarelli Flour and bakery products mixed with Aloe Vera or Aloe Vera "Apulian Snacks" Gel
IT201600124013A1 (en) * 2016-12-06 2018-06-06 Solarpharm Srl Astaxanthin based food product
CN108187034A (en) * 2017-07-28 2018-06-22 楼良水 Cordyceps sinensis composite fungi amylose piece
CN109010600A (en) * 2018-08-30 2018-12-18 宁波珐菲亚食品股份有限公司 The luxuriant and rich with fragrance sub- wine of enamel
CN109090410A (en) * 2018-09-28 2018-12-28 杨声显 A kind of living body Chinese medicine compound probiotic drink and preparation method thereof
CN109475151A (en) * 2016-06-24 2019-03-15 叶塞纳吉控股有限公司 Immunomodulatory and growth-promoting compositions for controlling harmful bacteria in the gut microbiota and uses thereof
EP3466276A1 (en) 2017-10-05 2019-04-10 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
EP3355893A4 (en) * 2015-09-29 2019-06-12 Kimberly-Clark Worldwide, Inc. SYNERGISTIC COMPOSITION FOR MAINTAINING A HEALTHY BALANCE OF THE MICROFLORE
CN110200830A (en) * 2019-05-23 2019-09-06 广州科斯曼生物科技有限公司 A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application
WO2019231776A1 (en) * 2018-05-31 2019-12-05 Kimberly-Clark Worldwide, Inc. Prebiotic compositions and methods for maintaining a healthy skin microbiota
CN110946782A (en) * 2019-12-27 2020-04-03 兰州大学 Application of Codonopsis oligosaccharides in the preparation of cosmetics
FR3097436A1 (en) * 2019-06-24 2020-12-25 L'oreal Cosmetic composition comprising a combination of at least one oligosaccharide and/or polysaccharide combined with a mannose monosaccharide
CN113575955A (en) * 2021-07-02 2021-11-02 青岛凯特生物科技有限公司 Prebiotic composition and preparation method thereof
US11389392B2 (en) 2017-06-13 2022-07-19 Mary Kay Inc. Cosmetic compositions and methods for their use in firming skin
RU2792104C2 (en) * 2018-05-31 2023-03-16 Кимберли-Кларк Ворлдвайд, Инк. Prebiotic-based compositions and methods for maintaining healthy skin microbiota
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US20250161208A1 (en) * 2021-06-04 2025-05-22 Quest Products, Llc Orally Adhering Lozenges Containing Soluble Dietary Fiber
US12485089B1 (en) 2025-03-13 2025-12-02 Quest Products, Llc Adhering lozenge with high amount of sparsely soluble active ingredient

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017172B2 (en) 2005-08-25 2011-09-13 Conagra Foods Food Ingredients Company, Inc. Whole grain flour and products including same
AU2004299117B2 (en) * 2003-12-17 2010-11-11 Ardent Mills Llc A process for producing an ultrafine-milled whole-grain wheat flour and products thereof
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
WO2009110816A1 (en) * 2008-03-04 2009-09-11 Dikovskiy Aleksander Vladimiro Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (en) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US20110070337A1 (en) * 2009-09-21 2011-03-24 Whitewave Services, Inc. Reduced Calorie Soy Beverage
US20110097427A1 (en) * 2009-10-27 2011-04-28 Shyam Ramakrishnan Molecular Targets and Dietary Modulators of Exercise-Induced Muscle Damage
US20110123677A1 (en) * 2009-11-25 2011-05-26 Pepsico, Inc. High acid beverage products and methods to extend probiotic stability
PL2529004T3 (en) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
AR082682A1 (en) 2010-08-13 2012-12-26 Advanced Bionutrition Corp STABILIZING DRY STORAGE COMPOSITION FOR BIOLOGICAL MATERIALS
US8574639B2 (en) 2010-08-17 2013-11-05 ILHWA Co., Ltd. Fermented ginseng concentrate having IH-901
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US8597697B2 (en) 2011-06-24 2013-12-03 Nutragenesis, Llc Composition of beta-glucan and ashwagandha
JP5877902B2 (en) 2011-08-17 2016-03-08 マイクロバイオーム セラピューティクス，エルエルシー Use of Compositions and Formulations to Increase the Ratio of Bacteroides Gastrointestinal Microbial Relative Firmictes Microflora
JP5785500B2 (en) * 2012-01-11 2015-09-30 株式会社ヤクルト本社 Paffia extract-containing beverage
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
CN102813116A (en) * 2012-09-07 2012-12-12 廖衍庆 Health-care food
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
US20150126463A1 (en) * 2013-11-04 2015-05-07 Hong Kong Baptist University Use of herbal saponins to regulate gut microflora
GB201319525D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
CN104225004B (en) * 2014-08-28 2017-11-21 广西壮族自治区药用植物园 A kind of adjunct antineoplastic Chinese medicine preparation containing pfaffia
CN104738632A (en) * 2015-04-10 2015-07-01 广西大学 Chickpea, konjak and cactus health nutrition powder and preparation method thereof
CN104738633A (en) * 2015-04-10 2015-07-01 广西大学 Kidney bean, jerusalem artichoke and purslane health nutrition powder and production method thereof
CN105055438A (en) * 2015-07-21 2015-11-18 珲春市神怡菌业生物科技开发有限公司 Lentinan prebiotic composition with gastrointestinal tract function improving effect
CN104997009B (en) * 2015-07-25 2018-06-15 云南蓝钻生物科技股份有限公司 A kind of health food of anti-aging strengthen immunity and preparation method thereof
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
CN104970369B (en) * 2015-08-05 2017-06-27 海南正康药业有限公司 A kind of health food of strengthen immunity and preparation method thereof
EP4282476A3 (en) 2015-12-18 2024-07-24 Mary Kay Inc. Topical cosmetic compositions
CN105497427A (en) * 2016-01-23 2016-04-20 李汶峰 Traditional Chinese medicine for treating prostatic hyperplasia
WO2017173240A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
EP3436041B1 (en) 2016-03-31 2023-05-24 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CA3019127A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Topical composition for reducing pathogen binding
AU2017240064B8 (en) 2016-03-31 2021-11-11 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
JP2020500860A (en) 2016-11-23 2020-01-16 ゴジョ・インダストリーズ・インコーポレイテッド Disinfectant compositions containing probiotic / prebiotic active ingredients
JP7031662B2 (en) 2017-03-28 2022-03-08 味の素株式会社 Foods for improving the intestinal environment
CN107198250B (en) * 2017-05-23 2019-03-12 北京瑞千景科技发展有限公司 Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application
WO2018237109A1 (en) * 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
BR102017019186A2 (en) * 2017-09-06 2018-02-27 Yessinergy Holding S/A COMPOSITION OF GROWTH PROMOTER PREBIOTIC ADDITIVES FOR ANIMAL FEED AND THEIR USE
CA3078545A1 (en) 2017-10-06 2019-04-11 Cargill, Incorporated Stabilized steviol glycoside compositions and uses thereof
CN108420890B (en) * 2018-03-21 2021-04-20 江苏康缘药业股份有限公司 Composition with blood fat reducing effect and preparation method thereof
CN108669530A (en) * 2018-05-24 2018-10-19 南京中生生物科技有限公司 A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health
EP3952667A1 (en) 2019-04-06 2022-02-16 Cargill, Incorporated Sensory modifiers
US20200352206A1 (en) * 2019-05-08 2020-11-12 Christine Wagner-Salvini Composition and method for mushroom mycelial compound and botanical mixture
CN110123823B (en) * 2019-06-27 2022-02-01 湖北中医药大学 Application of poria cocos oligosaccharide and pharmaceutical composition for treating glycolipid metabolic disorder diseases
WO2022165420A1 (en) * 2021-02-01 2022-08-04 Azitra Inc Methods and compositions for increasing protein expression in genetically engineered bacteria
CN113424954A (en) * 2021-07-30 2021-09-24 江西正和大健康产业有限公司 Edible fungus composition preparation and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501869A (en) * 1992-12-28 1996-03-26 Kraft Foods, Inc. Fat-free tablespread and method of making
FR2709061B1 (en) * 1993-08-17 1996-07-19 Ladislas Robert Use of oligosaccharides in the prevention and treatment of tissue aging.
FI109327B (en) * 1998-02-27 2002-07-15 Spice Sciences Oy Process for the preparation of a fat-like mixture of beta-sitosterol which lowers total serum and LDL cholesterol levels
WO2001078522A2 (en) * 2000-04-12 2001-10-25 Mid-America Commercialization Corporation Tasty, convenient, nutritionally balanced food compositions
DE10109708A1 (en) * 2001-02-11 2002-09-05 Aquanova Getraenketechnologie Improving solubility and incorporation of phytosterol in foods, nutritional supplements or body care agents by using a concentrate containing an emulsifier such as a polysorbate
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
FI20010780A0 (en) * 2001-04-12 2001-04-12 Raisio Benecol Oy Improved compositions
WO2005036971A1 (en) * 2003-10-16 2005-04-28 Techcom Group, Llc Reduced digestible carbohydrate food having reduced blood glucose response

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192730B2 (en) 2004-03-08 2012-06-05 Conopco, Inc. Hair treatment composition comprising sugar lactone
WO2008080701A1 (en) * 2007-01-02 2008-07-10 Henkel Ag & Co. Kgaa Cosmetic compositions containing selected fatty acids and squalene
WO2008110399A1 (en) * 2007-03-14 2008-09-18 Unilever Plc Method of treating hair with a sugar composition
US8192728B2 (en) 2007-03-14 2012-06-05 Conopco, Inc. Method of treating hair with a sugar composition
FR2916634A1 (en) * 2007-06-01 2008-12-05 Jean Noel Thorel Synergistic combination, useful e.g. as regulating agent of microbial flora of skin and to prepare cosmetic or pharmaceutical composition to treat oily or mixed skin, of fructo-oligosaccharides and inducer of antimicrobial peptide
EP2014181A3 (en) * 2007-06-15 2009-02-18 S.I.I.T. S.r.l. Servizio Internazionale Imballaggi Termosaldanti Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora
US8273335B2 (en) 2007-10-10 2012-09-25 Conopco, Inc. Method of treating hair
CN101491668B (en) * 2008-01-23 2012-11-07 北京因科瑞斯医药科技有限公司 Composition with blood-sugar reducing function and preparation method thereof
EA016865B1 (en) * 2008-02-05 2012-08-30 Унилевер Нв Method of treating hair
WO2009097885A1 (en) * 2008-02-05 2009-08-13 Unilever Plc Method of treating hair
US8187582B2 (en) 2008-03-28 2012-05-29 Conopco, Inc. Hair styling composition
US8673375B2 (en) 2008-04-10 2014-03-18 Prime Interaction Holdings Limited Herbal extract products and methods
GB2459121A (en) * 2008-04-10 2009-10-14 Prime Interaction Holdings Ltd A product for topical administration
US9725585B2 (en) 2008-07-18 2017-08-08 Roquette Freres Composition of soluble indigestible fibers and of eukaryotic organisms with a polysaccharide wall, used in the well-being field
WO2010007332A3 (en) * 2008-07-18 2010-04-22 Roquette Freres Composition of branched maltodextrins and eukaryotic organisms having a polysaccharide wall, used in the field of well-being
US9758644B2 (en) 2008-07-18 2017-09-12 Roquette Freres Composition of soluble indigestible fibre and of microalgae used in the well-being field
WO2010007331A3 (en) * 2008-07-18 2010-04-08 Roquette Freres Composition of soluble indigestible fibre and of microalgae used in the well-being field
FR2933848A1 (en) * 2008-07-18 2010-01-22 Roquette Freres COMPOSITION OF SOLUBLE INDIGESTIBLE FIBERS AND EUKARYOTIC ORGANISMS HAVING POLYSACCHARIDE WAVES USED IN THE WELL-BEING FIELD
WO2010106384A1 (en) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Glucooligosaccharide nutraceutical, pharmaceutical, or food compositions
US20120070521A1 (en) * 2009-05-22 2012-03-22 Bio-Ved Pharmaceuticals, PVT., Ltd. Method of extraction from withania somnifera and one or more fractions containing pharmacologically active ingredients obtained therefrom
WO2010150051A1 (en) * 2009-06-24 2010-12-29 Lipoid Gmbh Composition for cosmetic, pharmaceutical or dietary applications
FR2935228A1 (en) * 2009-09-30 2010-03-05 Roquette Freres Composition, useful e.g. for inducing the growth of the intestinal flora and treating or preventing e.g. cancer and chronic inflammatory bowel disease, comprises eukaryotic organisms with polysaccharide wall and branched maltodextrins
WO2011113501A1 (en) * 2010-03-15 2011-09-22 Henkel Ag & Co. Kgaa Hair treatment agent having at least four selected oils
EP2478779A1 (en) * 2011-01-24 2012-07-25 Biotechnobel Composition for providing beneficial health effects
BE1020284A3 (en) * 2011-01-24 2013-07-02 Biotechnobel COMPOSITION TO OBTAIN POSITIVE HEALTH EFFECTS.
WO2012113677A1 (en) 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotic carbohydrate compositions
DE102011012494A1 (en) 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotic carbohydrate compositions
CN104105471B (en) * 2012-02-14 2018-03-13 宝洁公司 Skin symbiosis prebiotics agent and the local use comprising its composition
CN104105471A (en) * 2012-02-14 2014-10-15 宝洁公司 Topical use of skin-commensal prebiotic agent and compositions containing same
CN104105470A (en) * 2012-02-14 2014-10-15 宝洁公司 Topical use of a skin-commensal prebiotic agent and compositions containing the same
ITRM20120084A1 (en) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola PREBIOTIC MIXTURE.
WO2013132456A1 (en) * 2012-03-07 2013-09-12 Aboca Societa' S.P.A. Societa' Agricola Prebiotic mixture
US9907827B2 (en) 2012-03-07 2018-03-06 Aboca S.P.A. Societá Agricola Prebiotic mixture
CN102670729A (en) * 2012-05-16 2012-09-19 乌鲁木齐市生命核力高科有限公司 Preparation method for cistanche tubulosa and American ginseng compound capsule
US11771674B2 (en) 2013-07-05 2023-10-03 Raisio Nutrition Ltd Edible composition suitable for lowering serum cholesterol
US10695313B2 (en) 2013-07-05 2020-06-30 Raisio Nutrition Ltd Edible composition suitable for lowering serum cholesterol
WO2015001175A1 (en) * 2013-07-05 2015-01-08 Raisio Nutrition Ltd Edible composition suitable for lowering serum cholesterol
US10874702B2 (en) 2014-03-13 2020-12-29 Procare Health Iberia, S.L. Topical compositions comprising extract of Coriolus versicolor for autoimmunity enhancement
US11524039B2 (en) 2014-03-13 2022-12-13 Procare Health Iberia, S.L. Topical compositions comprising extract of Coriolus versicolor for autoimmunity enhancement
WO2015136096A1 (en) * 2014-03-13 2015-09-17 Procare Health Iberia, S.L. Topical compositions comprising extract of coriolus versicolor for autoimmunity enhancement
EP3138414A4 (en) * 2014-08-07 2017-06-07 Mingfu Lu Comprehensive nutrition powder and preparation method therefor
DE102015100923A1 (en) * 2014-08-07 2016-02-11 Mingfu LU Integrated nutritional powder and process for its preparation
RU2579217C1 (en) * 2015-02-17 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный университет" (национальный исследовательский университет) (ФГБОУ ВПО "ЮУрГУ" (НИУ)) Enriched bakery product with antioxidant properties
CN105079777B (en) * 2015-08-05 2017-12-26 山东金城生物药业有限公司 Composition that is anti-oxidant, improving immunity and its preparation method and application
CN105079777A (en) * 2015-08-05 2015-11-25 山东金城生物药业有限公司 Anti-oxidative and immunity-enhancing composition as well as preparation method and application thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
AU2015410635B2 (en) * 2015-09-29 2021-08-19 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US12419898B2 (en) 2015-09-29 2025-09-23 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
EP3355893A4 (en) * 2015-09-29 2019-06-12 Kimberly-Clark Worldwide, Inc. SYNERGISTIC COMPOSITION FOR MAINTAINING A HEALTHY BALANCE OF THE MICROFLORE
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CN105250437A (en) * 2015-11-17 2016-01-20 金平金岭生物瑶药开发有限责任公司 Yao bath powder special for gynecology
CN105250437B (en) * 2015-11-17 2019-02-26 金平金岭生物瑶药开发有限责任公司 The dedicated precious jade bath powder of gynaecology
CN105420119B (en) * 2015-12-14 2019-05-31 中国人民解放军第二军医大学 Ginseng endophytic fungi and their applications
CN105420119A (en) * 2015-12-14 2016-03-23 中国人民解放军第二军医大学 Ginseng endophytic fungus and application thereof
ITUA20162240A1 (en) * 2016-04-13 2017-10-13 Maria Rosaria Ficarelli Flour and bakery products mixed with Aloe Vera or Aloe Vera "Apulian Snacks" Gel
CN109475151A (en) * 2016-06-24 2019-03-15 叶塞纳吉控股有限公司 Immunomodulatory and growth-promoting compositions for controlling harmful bacteria in the gut microbiota and uses thereof
EP3476226A4 (en) * 2016-06-24 2019-12-04 Yessinergy Holding s/a IMMUNOMODULATORY COMPOSITION PROMOTING GROWTH AND CONTROL OF POPULATION OF ADVERSE BACTERIA OF INTESTINAL MICROBIOTE, AND USE THEREOF
IT201600124013A1 (en) * 2016-12-06 2018-06-06 Solarpharm Srl Astaxanthin based food product
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11389392B2 (en) 2017-06-13 2022-07-19 Mary Kay Inc. Cosmetic compositions and methods for their use in firming skin
CN108187034A (en) * 2017-07-28 2018-06-22 楼良水 Cordyceps sinensis composite fungi amylose piece
EP3466276A1 (en) 2017-10-05 2019-04-10 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
WO2019068466A1 (en) 2017-10-05 2019-04-11 Pharmactive Biotech Products, S.L. Dietary fiber composition for protecting bioactive compounds during the physiological digestion process
CN112105351A (en) * 2018-05-31 2020-12-18 金伯利-克拉克环球有限公司 Prebiotic compositions and methods for maintaining a healthy skin microbiota
GB2589234A (en) * 2018-05-31 2021-05-26 Kimberly Clark Co Prebiotic compositions and methods for maintaining a healthy skin microbiota
AU2019276906B2 (en) * 2018-05-31 2025-04-17 Kimberly-Clark Worldwide, Inc. Prebiotic compositions and methods for maintaining a healthy skin microbiota
WO2019231776A1 (en) * 2018-05-31 2019-12-05 Kimberly-Clark Worldwide, Inc. Prebiotic compositions and methods for maintaining a healthy skin microbiota
GB2589234B (en) * 2018-05-31 2022-08-31 Kimberly Clark Co Prebiotic compositions and methods for maintaining a healthy skin microbiota
RU2792104C2 (en) * 2018-05-31 2023-03-16 Кимберли-Кларк Ворлдвайд, Инк. Prebiotic-based compositions and methods for maintaining healthy skin microbiota
CN109010600A (en) * 2018-08-30 2018-12-18 宁波珐菲亚食品股份有限公司 The luxuriant and rich with fragrance sub- wine of enamel
CN109090410A (en) * 2018-09-28 2018-12-28 杨声显 A kind of living body Chinese medicine compound probiotic drink and preparation method thereof
CN110200830A (en) * 2019-05-23 2019-09-06 广州科斯曼生物科技有限公司 A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application
FR3097436A1 (en) * 2019-06-24 2020-12-25 L'oreal Cosmetic composition comprising a combination of at least one oligosaccharide and/or polysaccharide combined with a mannose monosaccharide
WO2020260201A1 (en) * 2019-06-24 2020-12-30 L'oreal Cosmetic composition comprising a combination of at least one oligosaccharide and/or polysaccharide combined with a mannose monosaccharide, and use thereof in maintaining the balance of the bacterial skin flora
CN110946782A (en) * 2019-12-27 2020-04-03 兰州大学 Application of Codonopsis oligosaccharides in the preparation of cosmetics
US20250161208A1 (en) * 2021-06-04 2025-05-22 Quest Products, Llc Orally Adhering Lozenges Containing Soluble Dietary Fiber
CN113575955A (en) * 2021-07-02 2021-11-02 青岛凯特生物科技有限公司 Prebiotic composition and preparation method thereof
US12485089B1 (en) 2025-03-13 2025-12-02 Quest Products, Llc Adhering lozenge with high amount of sparsely soluble active ingredient

Also Published As

Publication number Publication date
SI1893221T1 (en) 2021-08-31
HU0500582D0 (en) 2005-08-29
WO2006134409A3 (en) 2007-03-01
EA200800034A1 (en) 2008-06-30
HUP0500582A1 (en) 2007-08-28
EP1893221A2 (en) 2008-03-05
CA2611935C (en) 2014-12-30
HUE053515T2 (en) 2021-07-28
EP1893221B1 (en) 2020-12-16
US20080261916A1 (en) 2008-10-23
EP1893221B8 (en) 2021-03-31
US20120121621A1 (en) 2012-05-17
EA017289B1 (en) 2012-11-30
CA2611935A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
CA2611935C (en) Synergistic prebiotic compositions
Tester et al. Glucomannans and nutrition
CA2449059C (en) Polymer controlled induced viscosity fiber system and uses thereof
EP2323669B2 (en) Arabinoxylan for modulating the barrier function of the intestinal surface
KR100516532B1 (en) Inulin Products with Improved Nutritional Properties
JP5645876B2 (en) A dietary fiber composition comprising glucomannan, xanthan gum and alginate
AU2019285716A1 (en) Intact pea protein-based nutrient composition
JP2018164453A (en) Enteric flora edible composition
EP0998206B1 (en) Functional food preparate
CN108208843A (en) A kind of health composition for adjusting intestinal flora and application thereof
CN107616490A (en) A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof
Katke et al. Review on psyllium husk (plantago ovata): A novel superfood for human health
KR102000170B1 (en) Food compositions for reducing body fat and improving intestinal function
CN104171858A (en) Nutritious eupeptic stage-2 infant formula rice flour
US20060286260A1 (en) Quick dissolving agglomerated soluble fiber compositions and the process for making the same
JP2015514411A (en) Combination of β-glucan and arabinoxylan
US20170348361A1 (en) Probiotic augmentation of anti-tumor endothelium immune responses
KR20210051214A (en) Manufacturing of ginseng shaped food with health functional food comprising products and method for manufacturing thereof
JP2009034017A (en) Diet food
Cozzolino et al. Functional food: Product development and health benefits
Modzelewska-Kapitula et al. Bioavailability of calcium and phosphorus from diets containing white cheeses supplemented with prebiotics in rats
CN116135035A (en) Dietary fiber beverage solid beverage formula and preparation method thereof
Vergara-Castañeda et al. Oligosaccharides: A Key for Gut Health
Pant et al. Horticultural crops as a source of prebiotics
Gupta et al. Current Research and Future Trends In Prebiotics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2611935

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006744405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800034

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006744405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11917236

Country of ref document: US